Antimicrobial Drug News and Research RSS Feed - Antimicrobial Drug News and Research

Antimicrobials are substance that kills microorganisms such as bacteria or mold, or stops them from growing and causing disease.
Survey finds prevalence of antimicrobial-drug use in U.S. hospitals

Survey finds prevalence of antimicrobial-drug use in U.S. hospitals

A one-day prevalence survey of 183 hospitals found that approximately 50 percent of hospitalized patients included in the survey were receiving antimicrobial drugs, and that about half of these patients were receiving 2 or more antimicrobial drugs, according to a study in the October 8 JAMA, a theme issue on infectious disease. Most antimicrobial use was for infection treatment. [More]
TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS Pharmaceuticals, Inc. today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. of Atlanta, GA. [More]
Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemopre­vention is to arrest or reverse the progression of pre­malignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells. [More]
Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research. [More]
Research to understand exactly how bleach kills bacteria

Research to understand exactly how bleach kills bacteria

Spring cleaning often involves chlorine bleach, which has been used as a disinfectant for hundreds of years. But our bodies have been using bleach's active component, hypochlorous acid, to help clean house for millennia. As part of our natural response to infection, certain types of immune cells produce hypochlorous acid to help kill invading microbes, including bacteria. [More]
Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine. [More]
Doctoral research shows role of immune system in development of resistance to antibiotics

Doctoral research shows role of immune system in development of resistance to antibiotics

Leon Cantas' doctoral research shows that the immune response of the host to a bacterial infection may have a significant effect on the development of bacteria's resistance to antibiotics. [More]
Microbiology testing services now offered by Ceram

Microbiology testing services now offered by Ceram

Ceram, the international materials testing and development company, has announced that it is now offering microbiology testing services for the healthcare industries, thanks to a partnership with a leading UK microbiological testing lab. [More]
International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422. [More]
Semprus BioSciences to develop surface-modified endotracheal tube

Semprus BioSciences to develop surface-modified endotracheal tube

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has announced that Semprus BioSciences, a wholly owned subsidiary of Teleflex Incorporated, has been awarded the initial phase of a $2.3 million research grant from the U.S. Army's Telemedicine and Advanced Technology Research Center (TATRC), located at Fort Detrick, MD. [More]
Biomedical scientists identify set of genes essential for A. baumannii gram-negative bacteria

Biomedical scientists identify set of genes essential for A. baumannii gram-negative bacteria

Biomedical scientists collaborating on translational research at two Buffalo institutions are reporting the discovery of a novel, and heretofore unrecognized, set of genes essential for the growth of potentially lethal, drug-resistant bacteria. [More]
BioDiem granted European patent for antimicrobial drug

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina. [More]
Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology. [More]
Nanosphere receives FDA marketing approval for Verigene GP Blood Culture Nucleic Acid Test

Nanosphere receives FDA marketing approval for Verigene GP Blood Culture Nucleic Acid Test

The U.S. Food and Drug Administration today allowed marketing of the first nucleic acid test that can identify 12 different bacterial types known to cause bloodstream infections. [More]
Allergy risk in children linked to antibacterials in personal-care products

Allergy risk in children linked to antibacterials in personal-care products

Exposure to common antibacterial chemicals found in soap, toothpaste, mouthwash and other personal-care products may make children more prone to a wide range of food and environmental allergies, according to new research from Johns Hopkins Children’s Center. [More]
Ciprofloxacin, TMP-SMX no longer safe for outpatient urinary tract infection

Ciprofloxacin, TMP-SMX no longer safe for outpatient urinary tract infection

In a surveillance study of over 12 million bacteria, investigators at The George Washington University and Providence Hospital found E. coli antimicrobial resistance to ciprofloxacin, the most commonly prescribed antimicrobial for urinary tract infections in the U.S., increased over five-fold from 2000 to 2010. [More]
AVMA warns against further restrictions on cephalosporin usage in food animals that are not backed by science

AVMA warns against further restrictions on cephalosporin usage in food animals that are not backed by science

The American Veterinary Medical Association (AVMA) announced today that the FDA's order prohibiting certain uses of cephalosporins in food animals appears consistent with the current AVMA position on the limited prohibition on extra-label drug use, but warned against further restrictions not backed by science. [More]
Antibiotic-resistant Salmonella worries experts

Antibiotic-resistant Salmonella worries experts

According to an international team of researchers a strain of Salmonella that is resistant to important antibiotics has spread from Africa to Europe in recent years and has been spotted in a few samples of imported spices in the United States. [More]
Drug resistant gonorrhea discovered

Drug resistant gonorrhea discovered

Japanese scientists have found a superbug strain of gonorrhea that’s resistant to all available antibiotics. This can pose a threat to public health worldwide, infectious disease experts say. [More]

Lytix Biopharma completes two LTX-109 Phase I/IIa studies in MRSA, Gram+ skin infections

The Norwegian pharmaceutical company Lytix Biopharma today announces the successful completion of two Phase I/IIa studies with the topical antimicrobial drug Lytixar - one for nasal decolonisation of MRSA / MSSA bacteria and one for treatment of Gram+ skin infections. [More]